Applied Molecular Transport

Biotechnology - South San Francisco, California, United States

Applied Molecular Transport Employees
Derek Maclean

Vice President, Pharmaceutical Sciences

Contact Derek Maclean

Suzanne Vyvoda

Executive Director, Head of Clinical Operations

Contact Suzanne Vyvoda

Andrew Chang

Executive Director, Investor Relations and Corporate Communications

Contact Andrew Chang

Bo Kim

Senior Research Associate, Upstream Process Development

Contact Bo Kim

Qun Yin

Staff Scientist

Contact Qun Yin

View All Applied Molecular Transport Employees Contact All Applied Molecular Transport Employees
Applied Molecular Transport Details

Applied Molecular Therapeutics (AMT), a public biopharmaceutical company based in South San Francisco, California, is committed to developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases. AMT is leveraging its propriety technology platforms to create gastrointestinal (GI)-select therapeutics that harness naturally occurring transport and targeting mechanisms to cross the protective barrier of the intestinal epithelium (IE). Once across the IE, the therapeutics gain privileged access to the immune cell-rich environment of the GI tissue as well as the hepatic portal system and downstream systemic circulation. With this privileged access, AMT's goal is to develop transformative new oral therapeutic treatment options that offer patients greater efficacy and tolerability than available with today's therapeutics. AMT has a robust pipeline of oral biologic product opportunities, including AMT-101 which is currently in Phase 1b clinical development for the treatment of adults with ulcerative colitis (UC). AMT-101 is a novel, gut-selective, investigational oral biologic fusion protein of interleukin 10 (IL-10), an anti-inflammatory cytokine. Derived from AMT's proprietary platforms, AMT-101 is engineered to cross the selective barrier of the IE and enhance localized IL-10 directly within the immune-cell rich environment of GI tissue where up to 75 percent of immune cells reside. This direct targeting of the immune system creates the potential for AMT-101 to address, at its point of origin, the immune dysregulation that gives rise to UC and other inflammatory bowel diseases, and restore immune homeostasis with minimal systemic exposure and potentially fewer adverse events compared to systemic administration of IL-10. AMT has amassed a broad global IP portfolio surrounding its multiple technology platforms and therapeutic programs.

Applied Molecular Transport logo, Applied Molecular Transport contact details
Website: appliedmt.com
Employees: 51 - 200
HQ:
Location: South San Francisco, California, United States
Revenue:
Applied Molecular Transport Technologies
Email Providers

Outlook

CMS

WordPress.org

Fonts

Google Font API

Other

Microsoft Office 365

Search Marketing

Adobe Marketing Cloud

View All Technologies Used At Applied Molecular Transport

Contacting Applied Molecular Transport: Connect with Executives and Employees

Get in Touch with Applied Molecular Transport Executives and Employees

Connecting with Applied Molecular Transport's Executives and Workforce

Accessing Contact Information for Applied Molecular Transport Executives

Connecting with Applied Molecular Transport: Reach Out to Their Team

Discover How to Contact Applied Molecular Transport Executives and Staff

Looking to connect with Applied Molecular Transport executives or employees?

Seeking to Get in Touch with Applied Molecular Transport Executives or Staff?

Want to Reach Out to Applied Molecular Transport Executives or Team Members?

In Search of Contact Details for Applied Molecular Transport Professionals?

Connecting with Applied Molecular Transport: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z